Vaccine

Immunization against invasive disease caused by H. influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 8 weeks to 15 months of age born of HB_sAg-negative mothers

Infants born of HB_sAg-positive mothers or mothers of unknown HB_sAg status should receive hepatitis B immune globulin and hepatitis B vaccine (Recombinant) at birth and should complete the hepatitis B vaccination series given according to a particular schedule

C

Hypersensitivity to any component of the vaccine

If used in persons with malignancies or those receiving immunosuppressive therapy or who are otherwise immunocompromised, the expected immune response may not be obtained.

The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute febrile illness.

When administered during the same visit that DTP, OPV, IPV, Varicella Virus Vaccine, and M-M-R II vaccines are given, the rates of systemic reactions do not differ from those observed only when any of the vaccines are administered All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

1% to 10%:

Central nervous system: Fever (up to 102.2°F), irritability, lethargy

Gastrointestinal: Anorexia, diarrhea

Local: Irritation at injection site

<1%: Convulsions, fever (>102.2°F), vomiting, allergic or anaphylactic reactions (difficulty in breathing, hives, itching, swelling of eyes, face, unusual tiredness or weakness)

Store at 2°C to 8°C/36°F to 48°F

Hib conjugate vaccines use covalent binding of capsular polysaccharide of Haemophilus influenzae type b to OMPC carrier to produce an antigen which is postulated to convert a T-independent antigen into a T-dependent antigen to result in enhanced antibody response and on immunologic memory. Recombinant hepatitis B vaccine is a noninfectious subunit viral vaccine. The vaccine is derived from hepatitis B surface antigen (HB_sAg) produced through recombinant DNA techniques from yeast cells. The portion of the hepatitis B gene which codes for HB_sAg is cloned into yeast which is then cultured to produce hepatitis B vaccine.

The seroconversion following one dose of Hib vaccine for children 18 months or 24 months of age or older is 75% to 90% respectively

Onset of Hib serum antibody responses: 1-2 weeks after vaccination

Duration: Hib Immunity appears to last 1.5 years

Duration of action: Following all 3 doses of hepatitis B vaccine, immunity will last ~5-7 years

Infants (>8 weeks of age): I.M.: 0.5 mL at 2, 4, and 12-15 months of age (total of 3 doses)

Modified Schedule: Children who receive one dose of hepatitis B vaccine at or shortly after birth may receive Comvax™ on a schedule of 2,4, and 12-15 months of age

May use acetaminophen for postdose fever

Defer immunization if infection or febrile illness present

Injection: 7.5 mcg Haemophilus b PRP and 5 mcg HB_sAg/0.5 mL